| Literature DB >> 30019432 |
Michela Fregosi1,2,3,4, Alessandro Contestabile1,2,3,4, Simon Badoud1,2,3,4, Simon Borgognon1,2,3,4, Jérôme Cottet1,2,3,4, Jean-François Brunet5, Jocelyne Bloch6, Martin E Schwab7, Eric M Rouiller1,2,3,4.
Abstract
Functional recovery from central nervous system injury is likely to be partly due to a rearrangement of neural circuits. In this context, the corticobulbar (corticoreticular) motor projections onto different nuclei of the ponto-medullary reticular formation (PMRF) were investigated in 13 adult macaque monkeys after either, primary motor cortex injury (MCI) in the hand area, or spinal cord injury (SCI) or Parkinson's disease-like lesions of the nigro-striatal dopaminergic system (PD). A subgroup of animals in both MCI and SCI groups was treated with neurite growth promoting anti-Nogo-A antibodies, whereas all PD animals were treated with autologous neural cell ecosystems (ANCE). The anterograde tracer BDA was injected either in the premotor cortex (PM) or in the primary motor cortex (M1) to label and quantify corticobulbar axonal boutons terminaux and en passant in PMRF. As compared to intact animals, after MCI the density of corticobulbar projections from PM was strongly reduced but maintained their laterality dominance (ipsilateral), both in the presence or absence of anti-Nogo-A antibody treatment. In contrast, the density of corticobulbar projections from M1 was increased following opposite hemi-section of the cervical cord (at C7 level) and anti-Nogo-A antibody treatment, with maintenance of contralateral laterality bias. In PD monkeys, the density of corticobulbar projections from PM was strongly reduced, as well as that from M1, but to a lesser extent. In conclusion, the densities of corticobulbar projections from PM or M1 were affected in a variable manner, depending on the type of lesion/pathology and the treatment aimed to enhance functional recovery.Entities:
Keywords: Parkinson; anterograde tracing; brainstem; cortical lesion; motor cortex; nonhuman primate; spinal cord injury
Mesh:
Substances:
Year: 2018 PMID: 30019432 PMCID: PMC6175012 DOI: 10.1111/ejn.14074
Source DB: PubMed Journal: Eur J Neurosci ISSN: 0953-816X Impact factor: 3.386
Individual monkeys’ data
| Cortical lesion (MCI) | Parkinsonian lesion | Spinal cord lesion | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mk‐MO | Mk‐VA | Mk‐RO | Mk‐BI | Mk‐LY | Mk‐MI | Mk‐LL | Mk‐MY | Mk‐CG | Mk‐CP | Mk‐AC | Mk‐AP | Mk‐AG | |
| Species | M.fasc. | M.fasc. | M.fasc. | M.fasc. | M.fasc. | M.fasc. | M.fasc. | M.fasc. | M.fasc. | M.fasc. | M.fasc. | M.fasc. | M.fasc. |
| Sex | Male | Male | Male | Male | Female | Female | Female | Female | Male | Female | Male | Female | Male |
| Age sacrifice (rounded 0.5 years) | 6 | 6 | 4.5 | 6 | 7.5 | 9.5 | 7.5 | 9.5 | 4 | 7 | 4 | 6.5 | 3.5 |
| Age lesion (rounded 0.5 years) | 5.5 | 5.5 | 4 | 5 | 7 | 9 | 7 | 9 | 3.5 | 6.5 | 3.5 | 6 | 3 |
| Weight (sacrifice or lesion) | 5.6 | 4.9 | 3.2 | 5 | 3.3 | 3.3 | 3.6 | 4.3 | * | * | * | * | * |
| Lesion Type/Location | MCI | MCI | MCI | MCI | PD | PD | PD | PD | SCI | SCI | SCI | SCI | SCI |
| Lesioned hemisph./SC side | Left | Left | Left | Left | Both | Both | Both | Both | Left | Left | Left | Left | Left |
| Type of lesion | Ibo. acid | Ibo. acid | Ibo. acid | Ibo. acid | MPTP | MPTP | MPTP | MPTP | Hemi‐sec | Hemi‐sec | Hemi‐sec | Hemi‐sec | Hemi‐sec |
| Treatment | a‐NogoA | a‐NogoA | ‐ | ‐ | ANCE | ANCE | ANCE | ANCE | Control | Control | a‐NogoA | a‐NogoA | a‐NogoA |
| Tracer injected | BDA | BDA | BDA | BDA | BDA | BDA | BDA | BDA | BDA | BDA | BDA | BDA | BDA |
| Side injected with BDA | Left | Left | Left | Left | Right | Right | Right | Left | Right | Right | Right | Right | Right |
| BDA injection sites in: | PMd/PMv | PMd/PMv | PMd | PMd/PMv | M1 | M1 | PMd/PMv | PMd/PMv | M1 | M1 | M1 | M1 | M1 |
| BDA‐injected volume (μl) | 10.8 | 5 | 4.8 | 7.2 | 9 | 9 | 9.7 | 11.5 | 24 | 24 | 20 | 24 | 28 |
| Number of BDA inj. sites | 12 | 5 | 6 | 11 | 6 | 6 | 8 | 9 | 12 | 12 | 10 | 12 | 15 |
| Number of labelled CST axons | 1975 | 1312 | 543 | 1328 | 1671 | 1117 | 593 | 611 | 716 | 712 | 537 | 1024 | 1405 |
| Total volume of lesion (mm3) in the grey matter | 41.8 | 20 | 14 | 20.1 | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ |
| Number of ibo. acid sites | 20 | 11 | 12 | 29 | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ |
| Volume ibo. acid (μl) or MPTP (mg/kg) | 20 | 15.5 | 18 | 29.7 | 6.25 | 7.75 | 6.25 | 6.25 | ‐ | ‐ | ‐ | ‐ | ‐ |
| Volume lesion in postcentral gyrus (mm3) | 0 | 5.8 | 0 | 0 | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ |
| Number of ANCE sites | ‐ | ‐ | ‐ | ‐ | 6 (3/hr) | 6 (3/hr) | 6 (3/hr) | 6 (3/hr) | ‐ | ‐ | ‐ | ‐ | ‐ |
| Loss DA cells in SNpc (%) | ‐ | ‐ | ‐ | ‐ | −39% | −74% | −67% | −72% | ‐ | ‐ | ‐ | ‐ | ‐ |
| % decrease of 18F‐DOPA uptake in striatum post‐MPTP lesion | ‐ | ‐ | ‐ | ‐ | −17% | −79% | −84% | −81% | ‐ | ‐ | ‐ | ‐ | ‐ |
| % decrease of 18F‐DOPA uptake in striatum post‐ANCE transplantation | 0 | −68% | −70% | −60% | |||||||||
| Volume spinal lesion (mm3) | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ | 1.802 | 1.782 | 4.577 | 1.348 |
|
| Extent hemi‐cord lesion (%) | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ | 51 | 45 | 85 | 58 | 78 |
| Extent of grey matter cut (%) | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ | 73 | 77 | 100 | 85 | 81 |
The number of labelled corticospinal tract (CST) axons was used in each monkey to normalize the boutons data (see methods).
MCI, motor cortex injury (M1 hand representation unilaterally); PD, Parkinson's disease‐like lesions of the nigro‐striatal dopaminergic system; SCI, spinal cord injury (Hemi‐section at C7 level); a‐NogoA, treatment with anti‐Nogo‐A antibody; the monkeys Mk‐CG and Mk‐CP received a control antibody; the monkeys Mk‐RO and Mk‐BI were untreated; ANCE, autologous neural cell ecosystems (autologous adult neural progenitor cells reimplanted bilaterally in caudate nucleus and putamen, three sites per hemisphere); Ibo‐acid, ibotenic acid (with indication of the number of sites where it was injected in M1).
*Data not available.
aDerived from previous behavioural studies: Kaeser et al. (2010, 2011); Bashir et al. (2012); Hamadjida et al. (2012); Hoogewoud et al. (2013); Wyss et al. (2013). bDerived from previous behavioural studies: S. Badoud (Ph.D. thesis 2016); Badoud et al. (2017); Borgognon et al. (2017). cDerived from previous behavioural studies: Freund et al. (2006, 2007, 2009); Wannier‐Morino et al. (2008); Beaud et al. (2008); Hoogewoud et al. (2013). dPercentage decrease with reference to 18F‐Dopa uptake in striatum prelesion. It means that 18F‐Dopa uptake reincreased post‐ANCE transplantation as compared to post‐MPTP lesion, as recently reported (Borgognon et al., 2017). eLesion volume in Mk‐AG could not be determined due to a few missing histological sections.
Figure 1(a) On lateral view of the left hemisphere, reconstruction of the BDA injection site in PM (green) and of the M1 lesion (red) for the MCI monkeys (data derived from Hamadjida et al., 2012). For these PM injections, in addition to a dense core region (dark green), an additional halo part was visible where a less dense BDA spread was present. (b) Lateral view of the hemisphere in PD animals with BDA injection sites (green) in PM (top two monkeys) and in M1 (bottom two monkeys). (c) Lateral view of the right hemisphere in SCI monkeys with BDA injection sites (green) in M1. Next to each hemisphere, an inset illustrates the cervical cord lesion (blue or red area) in the same monkey, as seen on a frontal section of the cervical cord (derived from Freund et al., 2007; Beaud et al., 2008, 2012). In each panel (a, b, c), the treatment applied to each animal is indicated
Figure 3Scatter plots of the numbers of corticobulbar boutons observed in the different groups of monkeys subjected to motor cortex lesion (MCI), spinal cord injury (SCI) or MPTP intoxication (PD). For comparison, the data in intact monkeys (Fregosi et al., 2017) are represented by the range (yellow or light blue area) and the mean value (dashed horizontal line). The yellow area is for data in intact monkeys as a result of BDA injections in PM, whereas the blue area is for data in intact monkeys as a result of BDA injection in M1. In the monkeys subjected to MCI, SCI or PD, the BDA injection site (PM or M1) is indicated below the graph. Panel a is for the absolute numbers of corticobulbar boutons, whereas the panel b is for normalized numbers of corticobulbar boutons. Different symbols display either the total or individual numbers of boutons for the ipsilateral or contralateral PMRF (see legend on top of each panel). The presence/absence of treatment is indicated by filled or open symbols: filled symbols for anti‐Nogo‐A antibody in MCI or SCI monkeys as well as ANCE treatment in PD monkeys, and open symbols for untreated MCI monkeys or control antibody‐treated SCI monkeys respectively. Asterisks above the circle symbols indicate that the numbers of axonal boutons in PMRF were significantly different between the ipsilateral and contralateral sides of PMRF: *p < 0.05, **p < 0.01, ***p ≤ 0.001, ns is for nonstatistically significant difference between the two PMRF sides
Figure 2Typical distribution of corticobulbar axonal boutons in PMRF in six representative histological sections taken from an MCI monkey (panel a), from a PD monkey (panel b) and from an SCI monkey (panel c). Boutons in the ipsilateral PMRF are depicted in green, whereas those in the contralateral PMRF are depicted in blue. In addition, BDA‐labelled stem axons are shown in blue on the ipsilateral side and in purple contralaterally. For each monkey, the applied treatment is indicated in parentheses. On each section, the pyramid (Py), when outlined in red, corresponds to the ipsilateral side, with respect to the hemisphere injected with BDA (see Figure 1). See list of abbreviations
Percentages of functional recovery (“recov”) from the lesion (SCI, MCI or MPTP) assessed using various behavioural motor tasks
| Monkeys ID | Spinal cord injured (SCI) monkeys | ||||
|---|---|---|---|---|---|
| Mk‐CG | Mk‐CP | Mk‐AC | Mk‐AP | Mk‐AG | |
| Treatment | Control Ab | Control AB | Anti‐Nogo‐A‐Ab | Anti‐Nogo‐A‐Ab | Anti‐Nogo‐A‐Ab |
| % recov vert | 95 | 88 | 100 | 100 | 100 |
| % recov horiz | 85 | 83 | 100 | 95 | 100 |
| % recov total | 90 | 83 | 100 | 99 | 100 |
Manual dexterity was assessed in SCI and MCI monkeys based on the “modified Brinkman Board” task (e.g. Schmidlin et al., 2011) considering the scorea separately for the vertical slots (Vert), or the horizontal slots (Horiz) or grouping them (Total: all slots). In MCI monkeys, an additional task was considered, the Brinkman box (Hamadjida et al., 2012), in which the total time (in seconds) necessary to visit all slots (n = 20) was measured. In both SCI and MCI, the lesion resulted in total loss of manual dexterity (scores = 0; infinite total time) in the acute postlesion phase, lasting a few weeks. The percentage of recovery was assessed at the level of the postlesion plateau (with reference to prelesion plateau).
In MPTP monkeys, the percentage of functional recovery (“recov”) or improvement (“impr”) was assessed based on the Schneider score (Sch‐s), the time spent in freezing activity (fr‐a) and the traveled distance (dist). The percentage of improvement was measured by comparing the median values post‐ANCE implantation versus the post‐MPTP lesion (time window before ANCE; see Borgognon et al., 2017): less time in freezing activity, more distance travelled. Manual dexterity data in MPTP monkeys will be published later. Functional recovery data are taken from previous studies (Freund et al., 2009; Wannier‐Morino et al., 2008; Beaud et al., 2008, 2012; Wyss et al., 2013; Borgognon et al., 2017) . The percentage of recovery is to some extent related to the lesion volume (see lesion volume data in Table 1).
aNumber of pellets successfully retrieved in 30 s. bIn the Schneider‐score, the percentage of recovery represented the proportion of the total deficit present after MPTP lesion which disappeared after autologous cells implantation. For instance, a Schneider score of 5 postlesion which decreased to 1 postimplantation corresponded to an 80% recovery.
Corticobulbar projections from PM in MCI monkeys
| Mk‐MO | Mk‐VA | Mk‐RO | Mk‐BI | |
|---|---|---|---|---|
| Total nb. of boutons | 295 | 772 | 582 | 427 |
| Ipsilateral boutons | 225 | 475 | 473 | 185 |
| Contralateral boutons | 70 | 297 | 109 | 242 |
| % Ipsilateral |
|
|
|
|
| % Contralateral |
|
|
|
|
| Normalized nb. of boutons*1,000 Ipsi | 114 | 362 | 871 | 139 |
| Normalized nb. of boutons*1,000 Contra | 35 | 226 | 201 | 182 |
Numbers (nb.) of corticobulbar boutons (en passant and terminaux) in the brainstem given in absolute values (top three rows) and in normalized values (bottom two rows) for animals with cortical lesion in M1 hand area (MCI). The global percentages of boutons on the ipsilateral and contralateral sides are given in Bold. In all four monkeys, BDA was injected in PM. The monkeys Mk‐MO and Mk‐VA received the anti‐Nogo‐A antibody treatmenta, whereas the monkeys Mk‐RO and Mk‐BI were untreated. The numbers of labelled CS axons used for normalization in each monkey are given in Table 1.
Corticobulbar projections from PM or M1 in PD monkeys
| PM injections | M1 injections | |||
|---|---|---|---|---|
| Mk‐LL | Mk‐MY | Mk‐LY | Mk‐MI | |
| Total nb. of boutons | 132 | 174 | 127 | 62 |
| Ipsilateral boutons | 83 | 115 | 66 | 34 |
| Contralateral boutons | 49 | 59 | 61 | 28 |
| % Ipsilateral |
|
|
|
|
| % Contralateral |
|
|
|
|
| Normalized nb. of boutons*1,000 Ipsi | 140 | 188 | 39 | 30 |
| Normalized nb. of boutons*1,000 Contra | 83 | 97 | 37 | 25 |
Numbers (nb.) of boutons (en passant and terminaux) in the brainstem given in absolute values (top three rows) and in normalized values (bottom two rows) in PD animals. The global percentages of boutons on the ipsilateral and contralateral sides are given in bold. BDA was injected in PM in two monkeys (Mk‐LL, Mk‐MY), whereas it was injected in M1 in the other two monkeys (Mk‐LY, Mk‐MI). All monkeys were subjected to the ANCE treatment. The numbers of labelled CS axons used for normalization in each monkey are given in Table 1.
Corticobulbar projections from M1 in SCI monkeys
| Mk‐CG | Mk‐CP | Mk‐AC | Mk‐AP | Mk‐AG | |
|---|---|---|---|---|---|
| Total nb. of boutons | 546 | 1,263 | 733 | 2,576 | 5,142 |
| Ipsilateral boutons | 157 | 195 | 230 | 603 | 1,566 |
| Contralateral boutons | 389 | 1,068 | 503 | 1,973 | 3,576 |
| % Ipsilateral |
|
|
|
|
|
| % Contralateral |
|
|
|
|
|
| Normalized nb. of boutons*1,000 Ipsi | 219 | 274 | 428 | 589 | 1,115 |
| Normalized nb. of boutons*1,000 Contra | 543 | 1,500 | 937 | 1,927 | 2,545 |
Numbers (nb.) of boutons (en passant and terminaux) along the brainstem given in absolute value (three top rows) and in normalized values (two bottom rows) in SCI animals. The global percentages of boutons in the ipsilateral and contralateral sides are given in bold. BDA was injected in M1 in all five monkeys. The monkeys Mk‐CG and Mk‐CP received a control antibody, whereas the other three monkeysa were treated with the anti‐Nogo‐A antibody. The numbers of labelled CS axons used for normalization in each monkey are given in Table 1.